Could Regulatory Scrutiny Shift the Risk Profile for Aurinia Pharmaceuticals (AUPH)?

• In late September 2025, Aurinia Pharmaceuticals responded to public criticism from an FDA official who challenged the benefit and safety profile of its lupus nephritis drug, Lupkynis; the comments were later retracted and clarified as personal opinion rather than agency policy.
• The incident highlighted how public communications by regulatory figures, even when unofficial, can create significant uncertainty for companies heavily reliant on a single approved medicine.
• We'll examine how this heightened regulatory scrutiny and company response could influence Aurinia's near-term investment narrative and risk profile.

Find companies with promising cash flow potential yet trading below their fair value.

Aurinia Pharmaceuticals Investment Narrative Recap

To own Aurinia Pharmaceuticals shares, an investor should have conviction in both the long-term value of LUPKYNIS for lupus nephritis and Aurinia's ability to defend its franchise amid regulatory scrutiny. While the recent retracted FDA official’s comments introduced short-term volatility, the company's response and reaffirmed regulatory approval mean the near-term outlook remains most sensitive to real changes in regulatory or payer sentiment, with revenue dependency on LUPKYNIS still the overriding risk.

The most relevant company update is the FDA's April 2024 supplementary approval for LUPKYNIS long-term use, supported by three-year efficacy and safety data. This milestone reinforces Aurinia's core investment catalyst, ongoing market adoption and label strength, even as controversy puts a spotlight on the need for robust, confirmatory outcomes in the regulatory process. Yet, questions about exclusivity and future competition linger, particularly following this latest spotlight on FDA standards.

In contrast, investors should carefully consider how quickly payer or regulatory pressures on LUPKYNIS access could shift given the company's reliance on a single drug...

Read the full narrative on Aurinia Pharmaceuticals (it's free!)

Aurinia Pharmaceuticals' outlook projects $386.4 million in revenue and $141.3 million in earnings by 2028. This is based on an annual revenue growth rate of 14.1% and a $80.7 million increase in earnings from the current $60.6 million level.

Uncover how Aurinia Pharmaceuticals' forecasts yield a $11.71 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members provided five fair value estimates for Aurinia ranging widely from US$7.65 to US$26.99 per share. These differing viewpoints come at a time when regulatory scrutiny of LUPKYNIS and its long-term exclusivity may weigh heavily on future performance, so it pays to weigh several opinions.

Explore 5 other fair value estimates on Aurinia Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Build Your Own Aurinia Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Aurinia Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Aurinia Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Aurinia Pharmaceuticals' overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Outshine the giants: these 23 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com